BR112022015379A2 - Derivados de 3-pirrolidino-indol como agentes psicodélicos serotonérgicos para o tratamento de distúrbios do snc - Google Patents
Derivados de 3-pirrolidino-indol como agentes psicodélicos serotonérgicos para o tratamento de distúrbios do sncInfo
- Publication number
- BR112022015379A2 BR112022015379A2 BR112022015379A BR112022015379A BR112022015379A2 BR 112022015379 A2 BR112022015379 A2 BR 112022015379A2 BR 112022015379 A BR112022015379 A BR 112022015379A BR 112022015379 A BR112022015379 A BR 112022015379A BR 112022015379 A2 BR112022015379 A2 BR 112022015379A2
- Authority
- BR
- Brazil
- Prior art keywords
- indole derivatives
- pyrrolidino
- disorders
- treatment
- cns disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062969894P | 2020-02-04 | 2020-02-04 | |
| PCT/CA2021/050122 WO2021155467A1 (en) | 2020-02-04 | 2021-02-04 | 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022015379A2 true BR112022015379A2 (pt) | 2022-09-27 |
Family
ID=77199114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022015379A BR112022015379A2 (pt) | 2020-02-04 | 2021-02-04 | Derivados de 3-pirrolidino-indol como agentes psicodélicos serotonérgicos para o tratamento de distúrbios do snc |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11453689B2 (https=) |
| EP (1) | EP4100403A4 (https=) |
| JP (2) | JP7824222B2 (https=) |
| KR (1) | KR20220137085A (https=) |
| CN (1) | CN115380028A (https=) |
| AU (1) | AU2021215709A1 (https=) |
| BR (1) | BR112022015379A2 (https=) |
| CA (1) | CA3166940A1 (https=) |
| IL (1) | IL295374A (https=) |
| MX (1) | MX2022009528A (https=) |
| WO (1) | WO2021155467A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022015379A2 (pt) * | 2020-02-04 | 2022-09-27 | Mindset Pharma Inc | Derivados de 3-pirrolidino-indol como agentes psicodélicos serotonérgicos para o tratamento de distúrbios do snc |
| US12240813B2 (en) | 2020-05-19 | 2025-03-04 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| AU2022229037A1 (en) * | 2021-03-02 | 2023-09-28 | Mindset Pharma Inc. | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
| BR112023024688A2 (pt) * | 2021-05-26 | 2024-02-15 | Mindset Pharma Inc | Combinação de halucinógeno-ácido graxo |
| US20240286998A1 (en) * | 2021-06-02 | 2024-08-29 | Saint Joseph's University | Fluorinated tryptamine compounds, analogues thereof, and methods using same |
| CA3229361A1 (en) * | 2021-08-20 | 2023-02-23 | Abdelmalik Slassi | 3-cycloamino-indole compounds as serotonergic agents useful for the treatment of disorders related thereto |
| EP4452939A4 (en) * | 2021-12-24 | 2025-12-10 | Kuleon Llc | SEROTONINERGIC COMPOUNDS, POLYPODS, AND PROMEDICINAL PRODIGITS OF SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS |
| WO2023150547A2 (en) * | 2022-02-01 | 2023-08-10 | Caamtech, Inc. | Psychedelic compounds and their therapeutic uses |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| CA3248179A1 (en) * | 2022-04-19 | 2023-10-26 | Mindset Pharma Inc. | Indoline derivatives used as serotonergic agents useful for the treatment of disorders associated with them |
| US12396981B2 (en) | 2023-03-09 | 2025-08-26 | William Shulman | Methods of using DMT |
| WO2025104491A1 (en) | 2023-11-14 | 2025-05-22 | Mindset Pharma Inc. | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5545644A (en) | 1990-10-15 | 1996-08-13 | Pfizer Inc. | Indole derivatives |
| US5559129A (en) | 1990-10-15 | 1996-09-24 | Pfizer Inc | Indole derivatives |
| US5607951A (en) | 1990-10-15 | 1997-03-04 | Pfizer Inc | Indole derivatives |
| US5120749A (en) | 1991-02-20 | 1992-06-09 | Abbott Laboratories | Platelet activating antagonists |
| TW288010B (https=) * | 1992-03-05 | 1996-10-11 | Pfizer | |
| US5747501A (en) * | 1992-04-07 | 1998-05-05 | Pfizer, Inc. | Indole derivatives |
| KR960701865A (ko) * | 1993-04-22 | 1996-03-28 | 데이비드 존. 우드 | 편두통에 사용하는 5-HT1 유사 효능제인 인돌 유도체(Indole Derivatives as 5-HT, -Like Agonists for Use in Migraine) |
| AP486A (en) * | 1993-04-27 | 1996-04-16 | Pfizer | Indole derivatives. |
| FR2735774B1 (fr) | 1995-06-21 | 1997-09-12 | Sanofi Sa | Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant |
| CA2268399C (en) | 1996-10-31 | 2008-08-19 | Harbor Branch Oceanographic Institution, Inc. | Anti-neurogenic inflammatory compounds and compositions and methods of use thereof |
| US6100291A (en) | 1998-03-16 | 2000-08-08 | Allelix Biopharmaceuticals Inc. | Pyrrolidine-indole compounds having 5-HT6 affinity |
| GB9816263D0 (en) | 1998-07-24 | 1998-09-23 | Merck Sharp & Dohme | Therapeutic agents |
| US6218423B1 (en) | 1998-08-14 | 2001-04-17 | Gpi Nil Holdings, Inc. | Pyrrolidine derivatives for vision and memory disorders |
| GB9923314D0 (en) | 1999-10-01 | 1999-12-08 | Pfizer Ltd | Acylation process |
| AU2001269769A1 (en) | 2000-06-07 | 2001-12-17 | The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University | Methods for making bis-heterocyclic alkaloids |
| US7135479B2 (en) | 2002-09-12 | 2006-11-14 | Wyeth | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans |
| WO2004106298A1 (en) | 2003-05-30 | 2004-12-09 | Janssen Pharmaceutica N.V. | Indole derivatives with an improved antipsychotic activity |
| US7700612B2 (en) * | 2003-12-23 | 2010-04-20 | Abraxis Bioscience, Llc | Di-ester prodrugs of camptothecin, process for their preparation and their therapeutical applications |
| ATE474833T1 (de) | 2004-09-22 | 2010-08-15 | Janssen Pharmaceutica Nv | Inhibitoren der wechselwirkung zwischen mdm2 und p53 |
| ZA200709038B (en) | 2005-04-13 | 2009-01-28 | Neuraxon Inc | Substituted indole compounds having nos inhibitory activity |
| US8003624B2 (en) | 2005-08-25 | 2011-08-23 | Schering Corporation | Functionally selective ALPHA2C adrenoreceptor agonists |
| EP1981875B1 (en) | 2006-01-19 | 2014-04-16 | Janssen Pharmaceutica N.V. | Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase |
| US20090306137A1 (en) * | 2006-05-22 | 2009-12-10 | Wolfgang Curt D | Treatment for depressive disorders |
| US7964728B2 (en) | 2006-07-06 | 2011-06-21 | Solvay Pharmaceuticals B.V. | Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition |
| WO2008036967A2 (en) | 2006-09-22 | 2008-03-27 | Reddy Us Therapeutics, Inc. | Novel heterocyclic compounds as lasy activators |
| US20090014868A1 (en) | 2007-07-10 | 2009-01-15 | International Business Machines Corporation | Manufacturing ic chip in portions for later combining, and related structure |
| EA201000808A1 (ru) | 2007-11-16 | 2011-04-29 | Ньюраксон, Инк. | Индольные соединения и способы лечения висцеральной боли |
| US20100022581A1 (en) | 2008-07-02 | 2010-01-28 | Memory Pharmaceuticals Corporation | Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity |
| WO2010132072A1 (en) | 2009-05-15 | 2010-11-18 | Neuraxon, Inc | Treatment or prevention of migraine by dosing at aura |
| JP5959537B2 (ja) | 2011-01-28 | 2016-08-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換ピリジニル−ピリミジン及び医薬としてのその使用 |
| PL3160464T3 (pl) * | 2014-06-26 | 2018-12-31 | Contera Pharma Aps | 6-hydroksybuspiron do stosowania w leczeniu zaburzeń ruchowych |
| GB201511382D0 (en) | 2015-06-29 | 2015-08-12 | Imp Innovations Ltd | Novel compounds and their use in therapy |
| AU2016320645B2 (en) * | 2015-09-10 | 2019-02-28 | Suven Life Sciences Limited | Fluoroindole derivatives as muscarinic M1 receptor positive allosteric modulators |
| EP3519816A4 (en) | 2016-09-29 | 2020-05-06 | The Regents of the University of California | CONNECTIONS FOR INCREASING NEURONAL PLASTICITY |
| WO2018094106A2 (en) | 2016-11-16 | 2018-05-24 | University Of South Florida | ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES |
| EP3687514A4 (en) * | 2017-09-27 | 2021-06-30 | Ohio State Innovation Foundation | METHODS AND COMPOSITIONS FOR INHIBITING STAT3 |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US12090145B2 (en) | 2018-08-20 | 2024-09-17 | Yale University | Combination therapy for treating or preventing depression or other mood diseases |
| MA54877A (fr) | 2019-01-30 | 2021-12-08 | Diamond Therapeutics Inc | Compositions et méthodes comprenant un agoniste de récepteur 5ht destinées au traitement de troubles psychologiques, cognitifs, comportementaux et/ou d'humeur |
| CA3132731A1 (en) | 2019-03-07 | 2020-09-10 | University Of Padova | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations |
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| CA3160793A1 (en) | 2019-12-04 | 2021-06-10 | Neonmind Biosciences Inc. | Use of psilocin, psilocybin or analogs thereof in weight loss, treatment of obesity and compulsive eating disorder |
| BR112022015379A2 (pt) * | 2020-02-04 | 2022-09-27 | Mindset Pharma Inc | Derivados de 3-pirrolidino-indol como agentes psicodélicos serotonérgicos para o tratamento de distúrbios do snc |
| CA3166785A1 (en) | 2020-02-05 | 2021-08-12 | Yale University | Psychedelic treatment for headache disorders |
| US12240813B2 (en) | 2020-05-19 | 2025-03-04 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| EP3902541B1 (en) | 2020-06-02 | 2022-09-14 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| CN119285527A (zh) | 2020-06-30 | 2025-01-10 | 瑞安神经科学公司 | 色胺前药 |
| WO2022018709A1 (en) | 2020-07-21 | 2022-01-27 | Ai Pharmaceuticals Jamaica Limited | Compositions and methods for treatment of psychoses and psychotic disorders |
| US11000534B1 (en) | 2020-10-08 | 2021-05-11 | Lennham Pharmaceuticals, Inc. | Deuterated derivatives of psilocybin and uses thereof |
-
2021
- 2021-02-04 BR BR112022015379A patent/BR112022015379A2/pt unknown
- 2021-02-04 WO PCT/CA2021/050122 patent/WO2021155467A1/en not_active Ceased
- 2021-02-04 CA CA3166940A patent/CA3166940A1/en active Pending
- 2021-02-04 AU AU2021215709A patent/AU2021215709A1/en active Pending
- 2021-02-04 CN CN202180026721.8A patent/CN115380028A/zh active Pending
- 2021-02-04 MX MX2022009528A patent/MX2022009528A/es unknown
- 2021-02-04 KR KR1020227030622A patent/KR20220137085A/ko active Pending
- 2021-02-04 IL IL295374A patent/IL295374A/en unknown
- 2021-02-04 JP JP2022548039A patent/JP7824222B2/ja active Active
- 2021-02-04 EP EP21751045.2A patent/EP4100403A4/en active Pending
- 2021-07-28 US US17/387,864 patent/US11453689B2/en active Active
-
2022
- 2022-08-02 US US17/879,320 patent/US12054504B2/en active Active
-
2024
- 2024-06-19 US US18/747,540 patent/US20240336641A1/en active Pending
-
2025
- 2025-12-23 JP JP2025279101A patent/JP2026053548A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115380028A (zh) | 2022-11-22 |
| AU2021215709A1 (en) | 2022-09-01 |
| EP4100403A4 (en) | 2024-01-03 |
| US11453689B2 (en) | 2022-09-27 |
| JP2026053548A (ja) | 2026-03-25 |
| MX2022009528A (es) | 2022-11-14 |
| CA3166940A1 (en) | 2021-08-12 |
| IL295374A (en) | 2022-10-01 |
| EP4100403A1 (en) | 2022-12-14 |
| JP2023512821A (ja) | 2023-03-29 |
| US12054504B2 (en) | 2024-08-06 |
| US20240336641A1 (en) | 2024-10-10 |
| US20230105399A1 (en) | 2023-04-06 |
| KR20220137085A (ko) | 2022-10-11 |
| US20220017550A1 (en) | 2022-01-20 |
| WO2021155467A1 (en) | 2021-08-12 |
| JP7824222B2 (ja) | 2026-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022015379A2 (pt) | Derivados de 3-pirrolidino-indol como agentes psicodélicos serotonérgicos para o tratamento de distúrbios do snc | |
| BR112022015375A2 (pt) | Derivados de psilocina como agentes psicodélicos serotonérgicos para o tratamento de distúrbios do snc | |
| BR112023017754A2 (pt) | Derivados de indol como agentes serotonérgicos úteis para o tratamento de distúrbios relacionados com o mesmo | |
| MX2023006652A (es) | Derivados de amina-indol-3-ciclica como agentes serotonergicos para el tratamiento de trastornos del snc. | |
| BR112022020776A2 (pt) | Pirrolo[1,2-d][1,2,4]triazina-2-il-acetamidas como inibidores da via do inflamassoma de nlrp3 | |
| BR112022010561A2 (pt) | Compostos poli-heterocíclicos como inibidores de mettl3 | |
| BR112022020798A2 (pt) | Compostos tricíclicos como inibidores de nlrp3 | |
| BR112022020807A2 (pt) | Pirazolo[1,5-d][1,2,4]triazina-5(4h)-acetamidas como inibidores da trajetória de inflamassoma de nlrp3 | |
| BR112022024045A2 (pt) | Moduladores il-17a | |
| BRPI0514404A (pt) | aminas policìclicas substituìdas com arila, método para sua produção e seu uso como um medicamento | |
| BR112023002957A2 (pt) | Composto, composição farmacêutica, e, métodos para tratar narcolepsia e para tratar hipersonia em um sujeito mamífero | |
| BR112022023983A2 (pt) | Compostos terapêuticos | |
| BRPI0407253A (pt) | Heterociclil-3-sulfonilindazóis como ligandos 5-hidroxitriptamina-6 processo de preparação dos mesmos, seus usos na preparação de uma composição farmacêutica e composição farmacêutica compreendendo os referidos compostos | |
| BRPI0911243B8 (pt) | derivados de benzofurano, benzotiofeno, benzotiazol, e composição farmacêutica | |
| BRPI0415657A (pt) | derivados de alcanamina de diidrobenzofuranila como agonistas de 5ht2c | |
| BR112014011333B1 (pt) | composto, composição farmacêutica e uso do composto de fórmula | |
| BR112021020106A2 (pt) | Moduladores da via de resposta ao estresse inte-grado | |
| BR112014016648A2 (pt) | derivados policíclicos, processo de preparação e uso farmacêutico dos mesmos | |
| BR112022027101A2 (pt) | Anticorpos multiespecíficos que se ligam a bcma | |
| BRPI0507041A (pt) | composto derivados de sulfonamida para o tratamento de doenças seus usos, processo para a preparação dos compostos e combinação de compostos | |
| CR10387A (es) | Derivados de 6,7,8,9-tetrahidro-5h-pirimido[4,5-d]azepin-4-il] amina como moduladores del potencial transitorio de receptor vaillinoide 1 para el tratamiento de dolor | |
| BRPI0713443A2 (pt) | Derivados de piperazinila úteis no tratamento de doenças medianas por receptor gpr38, uso e composição farmacêutica contendo tais compostos e processos para preparação dos mesmos | |
| AR054786A1 (es) | (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1 | |
| MX2025001439A (es) | Dímeros de 3-etilamino-indol como agentes serotoninérgicos útiles para el tratamiento de trastornos relacionados con los mismos | |
| BRPI0508724A (pt) | derivados do fenilaminoetanol como agonistas do receptor beta2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |